Compare Infosys Limited (INFY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Novartis AG — how do they compare? Infosys Limited trades at $11.28 (market cap $46.65B), while Novartis AG trades at $155.6 (market cap $290.25B). The key difference: Novartis AG is far larger — about 6.2× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.63%). Which is the better fit depends on your goals.
| INFY | NVS | |
|---|---|---|
Market Cap | $46.65B | $290.25B |
Sector | Technology | Health |
52-Week High | $20.22 | $168.62 |
52-Week Low | $10.49 | $113.50 |
Enterprise Value | $43.87B | $330.27B |
Dividend Yield | 4.63% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.31, down 1.57% on the day, with a bullish technical signal despite bearish moving averages. The stock shows strong profitability with a 16.44% net income margin and 31.57% ROE, supported by recent earnings beats. Recent news highlights AI collaborations with firms like Sentara and GlobalFoundries, positioning the company for growth in enterprise AI services.
The outlook is cautiously optimistic with a consensus price target of $12.28, implying 8.6% upside. Risks include competitive pressures in IT services and potential volatility from sector-wide demand concerns, as seen with Accenture's recent outlook. Analyst sentiment is mixed, with 37.5% buy ratings but a majority hold stance, reflecting balanced near-term expectations.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
